Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Total Non-Current Liabilities (2023 - 2025)

Historic Total Non-Current Liabilities for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Q3 2025 value amounting to $62.2 million.

  • Day One Biopharmaceuticals' Total Non-Current Liabilities changed N/A to $62.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $62.2 million, marking a year-over-year change of. This contributed to the annual value of $79.3 million for FY2024, which is 16865.93% up from last year.
  • According to the latest figures from Q3 2025, Day One Biopharmaceuticals' Total Non-Current Liabilities is $62.2 million.
  • Day One Biopharmaceuticals' Total Non-Current Liabilities' 5-year high stood at $79.3 million during Q4 2024, with a 5-year trough of $29.5 million in Q4 2023.
  • Over the past 3 years, Day One Biopharmaceuticals' median Total Non-Current Liabilities value was $57.4 million (recorded in 2025), while the average stood at $56.5 million.
  • Within the past 5 years, the most significant YoY rise in Day One Biopharmaceuticals' Total Non-Current Liabilities was 16865.93% (2024), while the steepest drop was 16865.93% (2024).
  • Over the past 3 years, Day One Biopharmaceuticals' Total Non-Current Liabilities (Quarter) stood at $29.5 million in 2023, then skyrocketed by 168.66% to $79.3 million in 2024, then decreased by 21.6% to $62.2 million in 2025.
  • Its last three reported values are $62.2 million in Q3 2025, $57.4 million for Q2 2025, and $54.1 million during Q1 2025.